Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma (original) (raw)

. 1997 Apr;150(4):1141–1157.

Abstract

Chronic infection with hepatitis B virus is associated with a high incidence of liver diseases, including hepatocellular carcinoma. Hepatitis-B-virus-encoded X antigen (HBxAg) stimulates virus gene expression and replication, which may be important for the establishment and maintenance of the chronic carrier state. Integration of viral DNA encoding HBxAg during chronic infection results in increased X antigen expression. HBxAg overexpression may alter signal transduction pathways important for the regulation of cell growth during hepatocellular regeneration. The finding that HBxAg binds to and inactivates negative growth-regulatory molecules, such as the tumor suppressor p53, suggests additional ways that HBxAg may act in hepatocarcinogenesis. HBxAg may also stimulate the expression of positive growth regulators, such as insulin-like growth factor II and the insulin-like growth factor I receptor. The finding that HBxAg may compromise DNA repair and that it may effect the normal turnover of growth-regulatory molecules in the proteasome may also contribute to its carcinogenic properties. Hence, HBxAg may contribute to the pathogenesis of chronic infection and development of hepatocellular carcinoma in a variety of ways.

1141

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agoff S. N., Hou J., Linzer D. I., Wu B. Regulation of the human hsp70 promoter by p53. Science. 1993 Jan 1;259(5091):84–87. doi: 10.1126/science.8418500. [DOI] [PubMed] [Google Scholar]
  2. Antunović J., Lemieux N., Cromlish J. A. The 17 kDa HBx protein encoded by hepatitis B virus interacts with the activation domains of Oct-1, and functions as a coactivator in the activation and repression of a human U6 promoter. Cell Mol Biol Res. 1993;39(5):463–482. [PubMed] [Google Scholar]
  3. Balsano C., Billet O., Bennoun M., Cavard C., Zider A., Grimber G., Natoli G., Briand P., Levrero M. Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol. 1994 Jul;21(1):103–109. doi: 10.1016/s0168-8278(94)80144-4. [DOI] [PubMed] [Google Scholar]
  4. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 1995 Jan 15;55(2):249–252. [PubMed] [Google Scholar]
  5. Beasley R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988 May 15;61(10):1942–1956. doi: 10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  6. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  7. Beg A. A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996 Nov 1;274(5288):782–784. doi: 10.1126/science.274.5288.782. [DOI] [PubMed] [Google Scholar]
  8. Beg A. A., Sha W. C., Bronson R. T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995 Jul 13;376(6536):167–170. doi: 10.1038/376167a0. [DOI] [PubMed] [Google Scholar]
  9. Benn J., Schneider R. J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10350–10354. doi: 10.1073/pnas.91.22.10350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Benn J., Schneider R. J. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11215–11219. doi: 10.1073/pnas.92.24.11215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Blumberg B. S. Feasibility of controlling or eradicating the hepatitis B virus. Am J Med. 1989 Sep 4;87(3A):2S–4S. doi: 10.1016/0002-9343(89)90522-6. [DOI] [PubMed] [Google Scholar]
  12. Blumberg B. S., London W. T. Hepatitis B virus: pathogenesis and prevention of primary cancer of the liver. Cancer. 1982 Dec 1;50(11 Suppl):2657–2665. [PubMed] [Google Scholar]
  13. Bootsma D., Hoeijmakers J. H. DNA repair. Engagement with transcription. Nature. 1993 May 13;363(6425):114–115. doi: 10.1038/363114a0. [DOI] [PubMed] [Google Scholar]
  14. Cariani E., Lasserre C., Kemeny F., Franco D., Brechot C. Expression of insulin-like growth factor II, alpha-fetoprotein and hepatitis B virus transcripts in human primary liver cancer. Hepatology. 1991 Apr;13(4):644–649. [PubMed] [Google Scholar]
  15. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., Czech M. P., Ullrich A., Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988 Dec 1;48(23):6844–6849. [PubMed] [Google Scholar]
  16. Cerutti P. A. Prooxidant states and tumor promotion. Science. 1985 Jan 25;227(4685):375–381. doi: 10.1126/science.2981433. [DOI] [PubMed] [Google Scholar]
  17. Chen H. S., Kaneko S., Girones R., Anderson R. W., Hornbuckle W. E., Tennant B. C., Cote P. J., Gerin J. L., Purcell R. H., Miller R. H. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol. 1993 Mar;67(3):1218–1226. doi: 10.1128/jvi.67.3.1218-1226.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cheong J. H., Yi M., Lin Y., Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 1995 Jan 3;14(1):143–150. doi: 10.1002/j.1460-2075.1995.tb06984.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chesnut J. D., Stephens J. H., Dahmus M. E. The interaction of RNA polymerase II with the adenovirus-2 major late promoter is precluded by phosphorylation of the C-terminal domain of subunit IIa. J Biol Chem. 1992 May 25;267(15):10500–10506. [PubMed] [Google Scholar]
  20. Chisari F. V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H. A., Sell S., Pinkert C. A., Brinster R. L., Palmiter R. D. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989 Dec 22;59(6):1145–1156. doi: 10.1016/0092-8674(89)90770-8. [DOI] [PubMed] [Google Scholar]
  21. Ciechanover A., DiGiuseppe J. A., Bercovich B., Orian A., Richter J. D., Schwartz A. L., Brodeur G. M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):139–143. doi: 10.1073/pnas.88.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Colgrove R., Simon G., Ganem D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol. 1989 Sep;63(9):4019–4026. doi: 10.1128/jvi.63.9.4019-4026.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Cross J. C., Wen P., Rutter W. J. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8078–8082. doi: 10.1073/pnas.90.17.8078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Cyert M. S., Thorner J. Putting it on and taking it off: phosphoprotein phosphatase involvement in cell cycle regulation. Cell. 1989 Jun 16;57(6):891–893. doi: 10.1016/0092-8674(89)90325-5. [DOI] [PubMed] [Google Scholar]
  25. Dandri M., Schirmacher P., Rogler C. E. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol. 1996 Aug;70(8):5246–5254. doi: 10.1128/jvi.70.8.5246-5254.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Dejean A., Bougueleret L., Grzeschik K. H., Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature. 1986 Jul 3;322(6074):70–72. doi: 10.1038/322070a0. [DOI] [PubMed] [Google Scholar]
  27. Dejean A., Sonigo P., Wain-Hobson S., Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat. Proc Natl Acad Sci U S A. 1984 Sep;81(17):5350–5354. doi: 10.1073/pnas.81.17.5350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Dejean A., de Thé H. Hepatitis B virus as an insertional mutagene in a human hepatocellular carcinoma. Mol Biol Med. 1990 Jun;7(3):213–222. [PubMed] [Google Scholar]
  29. Diamantis I. D., McGandy C. E., Chen T. J., Liaw Y. F., Gudat F., Bianchi L. Hepatitis B X-gene expression in hepatocellular carcinoma. J Hepatol. 1992 Jul;15(3):400–403. doi: 10.1016/0168-8278(92)90077-3. [DOI] [PubMed] [Google Scholar]
  30. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A., Jr, Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19;356(6366):215–221. doi: 10.1038/356215a0. [DOI] [PubMed] [Google Scholar]
  31. Dragani T. A., Manenti G., Farza H., Della Porta G., Tiollais P., Pourcel C. Transgenic mice containing hepatitis B virus sequences are more susceptible to carcinogen-induced hepatocarcinogenesis. Carcinogenesis. 1990 Jun;11(6):953–956. doi: 10.1093/carcin/11.6.953. [DOI] [PubMed] [Google Scholar]
  32. Feitelson M. A., Clayton M. M., Blumberg B. S. X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum. Gastroenterology. 1990 Apr;98(4):1071–1078. doi: 10.1016/0016-5085(90)90035-y. [DOI] [PubMed] [Google Scholar]
  33. Feitelson M. A., Clayton M. M., Phimister B. Monoclonal antibodies raised to purified woodchuck hepatitis virus core antigen particles demonstrate X antigen reactivity. Virology. 1990 Jul;177(1):357–366. doi: 10.1016/0042-6822(90)90491-9. [DOI] [PubMed] [Google Scholar]
  34. Feitelson M. A., Clayton M. M. X antigen polypeptides in the sera of hepatitis B virus-infected patients. Virology. 1990 Jul;177(1):367–371. doi: 10.1016/0042-6822(90)90492-a. [DOI] [PubMed] [Google Scholar]
  35. Feitelson M. A. Hepatitis B virus gene products as immunological targets in chronic infection. Mol Biol Med. 1989 Oct;6(5):367–393. [PubMed] [Google Scholar]
  36. Feitelson M. A., Lega L., Duan L. X., Clayton M. Characteristics of woodchuck hepatitis X-antigen in the livers and sera from infected animals. J Hepatol. 1993;17 (Suppl 3):S24–S34. doi: 10.1016/s0168-8278(05)80420-9. [DOI] [PubMed] [Google Scholar]
  37. Feitelson M. A. Products of the "X" gene in hepatitis B and related viruses. Hepatology. 1986 Mar-Apr;6(2):191–198. doi: 10.1002/hep.1840060207. [DOI] [PubMed] [Google Scholar]
  38. Feitelson M. A., Zhu M., Duan L. X., London W. T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993 May;8(5):1109–1117. [PubMed] [Google Scholar]
  39. Feitelson M. Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev. 1992 Jul;5(3):275–301. doi: 10.1128/cmr.5.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Feitelson M., Lega L., Guo J., Resti M., Rossi M. E., Azzari C., Blumberg B. S., Vierucci A. Pathogenesis of posttransfusion viral hepatitis in children with beta-thalassemia. Hepatology. 1994 Mar;19(3):558–568. doi: 10.1002/hep.1840190304. [DOI] [PubMed] [Google Scholar]
  41. Fourel G., Trepo C., Bougueleret L., Henglein B., Ponzetto A., Tiollais P., Buendia M. A. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature. 1990 Sep 20;347(6290):294–298. doi: 10.1038/347294a0. [DOI] [PubMed] [Google Scholar]
  42. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993 Feb;8(2):307–318. [PubMed] [Google Scholar]
  43. Fu X. X., Su C. Y., Lee Y., Hintz R., Biempica L., Snyder R., Rogler C. E. Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol. 1988 Sep;62(9):3422–3430. doi: 10.1128/jvi.62.9.3422-3430.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Geller S. A., Nichols W. S., Kim S., Tolmachoff T., Lee S., Dycaico M. J., Felts K., Sorge J. A. Hepatocarcinogenesis is the sequel to hepatitis in Z#2 alpha 1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology. 1994 Feb;19(2):389–397. [PubMed] [Google Scholar]
  45. Gilles P. N., Fey G., Chisari F. V. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol. 1992 Jun;66(6):3955–3960. doi: 10.1128/jvi.66.6.3955-3960.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gordon J. W. Transgenic mouse models of hepatocellular carcinoma. Hepatology. 1994 Feb;19(2):538–539. [PubMed] [Google Scholar]
  47. Guilhot S., Guidotti L. G., Chisari F. V. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol. 1993 Dec;67(12):7444–7449. doi: 10.1128/jvi.67.12.7444-7449.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Guyton K. Z., Kensler T. W. Oxidative mechanisms in carcinogenesis. Br Med Bull. 1993 Jul;49(3):523–544. doi: 10.1093/oxfordjournals.bmb.a072628. [DOI] [PubMed] [Google Scholar]
  49. Hagen T. M., Huang S., Curnutte J., Fowler P., Martinez V., Wehr C. M., Ames B. N., Chisari F. V. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12808–12812. doi: 10.1073/pnas.91.26.12808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hainaut P., Milner J. Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J. 1992 Oct;11(10):3513–3520. doi: 10.1002/j.1460-2075.1992.tb05434.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Hatada I., Tokino T., Ochiya T., Matsubara K. Co-amplification of integrated hepatitis B virus DNA and transforming gene hst-1 in a hepatocellular carcinoma. Oncogene. 1988 Nov;3(5):537–540. [PubMed] [Google Scholar]
  52. Haviv I., Vaizel D., Shaul Y. The X protein of hepatitis B virus coactivates potent activation domains. Mol Cell Biol. 1995 Feb;15(2):1079–1085. doi: 10.1128/mcb.15.2.1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Haviv I., Vaizel D., Shaul Y. pX, the HBV-encoded coactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner. EMBO J. 1996 Jul 1;15(13):3413–3420. [PMC free article] [PubMed] [Google Scholar]
  54. Hino O., Nomura K., Ohtake K., Kawaguchi T., Sugano H., Kitagawa T. Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. Cancer Genet Cytogenet. 1989 Feb;37(2):273–278. doi: 10.1016/0165-4608(89)90059-9. [DOI] [PubMed] [Google Scholar]
  55. Hino O., Tabata S., Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9248–9252. doi: 10.1073/pnas.88.20.9248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hirohashi S., Shimosato Y., Ino Y., Kishi K. Distribution of hepatitis B surface and core antigens in human liver cell carcinoma and surrounding nontumorous liver. J Natl Cancer Inst. 1982 Sep;69(3):565–568. [PubMed] [Google Scholar]
  57. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  58. Hoofnagle J. H., Shafritz D. A., Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology. 1987 Jul-Aug;7(4):758–763. doi: 10.1002/hep.1840070424. [DOI] [PubMed] [Google Scholar]
  59. Hsu T., Möröy T., Etiemble J., Louise A., Trépo C., Tiollais P., Buendia M. A. Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell. 1988 Nov 18;55(4):627–635. doi: 10.1016/0092-8674(88)90221-8. [DOI] [PubMed] [Google Scholar]
  60. Huang J., Kwong J., Sun E. C., Liang T. J. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol. 1996 Aug;70(8):5582–5591. doi: 10.1128/jvi.70.8.5582-5591.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Höhne M., Schaefer S., Seifer M., Feitelson M. A., Paul D., Gerlich W. H. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J. 1990 Apr;9(4):1137–1145. doi: 10.1002/j.1460-2075.1990.tb08220.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Jhappan C., Stahle C., Harkins R. N., Fausto N., Smith G. H., Merlino G. T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell. 1990 Jun 15;61(6):1137–1146. doi: 10.1016/0092-8674(90)90076-q. [DOI] [PubMed] [Google Scholar]
  63. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13;71(4):587–597. doi: 10.1016/0092-8674(92)90593-2. [DOI] [PubMed] [Google Scholar]
  64. Kekulé A. S., Lauer U., Weiss L., Luber B., Hofschneider P. H. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature. 1993 Feb 25;361(6414):742–745. doi: 10.1038/361742a0. [DOI] [PubMed] [Google Scholar]
  65. Kim C. M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991 May 23;351(6324):317–320. doi: 10.1038/351317a0. [DOI] [PubMed] [Google Scholar]
  66. Kim S. O., Park J. G., Lee Y. I. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res. 1996 Aug 15;56(16):3831–3836. [PubMed] [Google Scholar]
  67. Koike K., Moriya K., Iino S., Yotsuyanagi H., Endo Y., Miyamura T., Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 1994 Apr;19(4):810–819. [PubMed] [Google Scholar]
  68. Koike K., Moriya K., Yotsuyanagi H., Iino S., Kurokawa K. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J Clin Invest. 1994 Jul;94(1):44–49. doi: 10.1172/JCI117343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Lee T. H., Finegold M. J., Shen R. F., DeMayo J. L., Woo S. L., Butel J. S. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol. 1990 Dec;64(12):5939–5947. doi: 10.1128/jvi.64.12.5939-5947.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Levine A. J. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology. 1990 Aug;177(2):419–426. doi: 10.1016/0042-6822(90)90505-l. [DOI] [PubMed] [Google Scholar]
  71. Li J., Tang Z. Y., Liu K. D., Schroder C. H. [Preparation of monoclonal antibody directed against hepatitis B virus X protein and detection of reactive antigen in hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi. 1994 Sep;74(9):533-5, 582. [PubMed] [Google Scholar]
  72. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  73. Luber B., Arnold N., Stürzl M., Höhne M., Schirmacher P., Lauer U., Wienberg J., Hofschneider P. H., Kekulé A. S. Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro. Oncogene. 1996 Apr 18;12(8):1597–1608. [PubMed] [Google Scholar]
  74. Lucito R., Schneider R. J. Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol. 1992 Feb;66(2):983–991. doi: 10.1128/jvi.66.2.983-991.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Maguire H. F., Hoeffler J. P., Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science. 1991 May 10;252(5007):842–844. doi: 10.1126/science.1827531. [DOI] [PubMed] [Google Scholar]
  76. Maki C. G., Huibregtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 1;56(11):2649–2654. [PubMed] [Google Scholar]
  77. Marion P. L., Van Davelaar M. J., Knight S. S., Salazar F. H., Garcia G., Popper H., Robinson W. S. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4543–4546. doi: 10.1073/pnas.83.12.4543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Matsubara K., Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med. 1990 Jun;7(3):243–260. [PubMed] [Google Scholar]
  79. Meyer M., Caselmann W. H., Schlüter V., Schreck R., Hofschneider P. H., Baeuerle P. A. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J. 1992 Aug;11(8):2991–3001. doi: 10.1002/j.1460-2075.1992.tb05369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  81. Moriyama T., Guilhot S., Klopchin K., Moss B., Pinkert C. A., Palmiter R. D., Brinster R. L., Kanagawa O., Chisari F. V. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990 Apr 20;248(4953):361–364. doi: 10.1126/science.1691527. [DOI] [PubMed] [Google Scholar]
  82. Murakami S., Cheong J., Ohno S., Matsushima K., Kaneko S. Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways. Virology. 1994 Feb 15;199(1):243–246. doi: 10.1006/viro.1994.1119. [DOI] [PubMed] [Google Scholar]
  83. Murakami Y., Hayashi K., Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res. 1991 Jul 1;51(13):3356–3361. [PubMed] [Google Scholar]
  84. Möröy T., Marchio A., Etiemble J., Trépo C., Tiollais P., Buendia M. A. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature. 1986 Nov 20;324(6094):276–279. doi: 10.1038/324276a0. [DOI] [PubMed] [Google Scholar]
  85. Nakatake H., Chisaka O., Yamamoto S., Matsubara K., Koshy R. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology. 1993 Aug;195(2):305–314. doi: 10.1006/viro.1993.1381. [DOI] [PubMed] [Google Scholar]
  86. Natoli G., Avantaggiati M. L., Chirillo P., Puri P. L., Ianni A., Balsano C., Levrero M. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene. 1994 Oct;9(10):2837–2843. [PubMed] [Google Scholar]
  87. Nomura A., Stemmermann G. N., Wasnich R. D. Presence of hepatitis B surface antigen before primary hepatocellular carcinoma. JAMA. 1982 Apr 23;247(16):2247–2249. [PubMed] [Google Scholar]
  88. Ogston C. W., Jonak G. J., Rogler C. E., Astrin S. M., Summers J. Cloning and structural analysis of integrated woodchuck hepatitis virus sequences from hepatocellular carcinomas of woodchucks. Cell. 1982 Jun;29(2):385–394. doi: 10.1016/0092-8674(82)90155-6. [DOI] [PubMed] [Google Scholar]
  89. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994 Mar 1;305(2):253–264. doi: 10.1016/0027-5107(94)90245-3. [DOI] [PubMed] [Google Scholar]
  90. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992 May;15(5):948–963. doi: 10.1002/hep.1840150532. [DOI] [PubMed] [Google Scholar]
  91. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80–83. doi: 10.1038/358080a0. [DOI] [PubMed] [Google Scholar]
  92. Ozer A., Khaoustov V. I., Mearns M., Lewis D. E., Genta R. M., Darlington G. J., Yoffe B. Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology. 1996 May;110(5):1519–1528. doi: 10.1053/gast.1996.v110.pm8613059. [DOI] [PubMed] [Google Scholar]
  93. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773–785. doi: 10.1016/s0092-8674(94)90482-0. [DOI] [PubMed] [Google Scholar]
  94. Paterlini P., Poussin K., Kew M., Franco D., Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995 Feb;21(2):313–321. [PubMed] [Google Scholar]
  95. Perrillo R. P. Antiviral therapy of chronic hepatitis B: past, present, and future. J Hepatol. 1993;17 (Suppl 3):S56–S63. doi: 10.1016/s0168-8278(05)80425-8. [DOI] [PubMed] [Google Scholar]
  96. Popper H., Roth L., Purcell R. H., Tennant B. C., Gerin J. L. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A. 1987 Feb;84(3):866–870. doi: 10.1073/pnas.84.3.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Qadri I., Maguire H. F., Siddiqui A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1003–1007. doi: 10.1073/pnas.92.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761–771. doi: 10.1016/s0092-8674(94)90462-6. [DOI] [PubMed] [Google Scholar]
  99. Rogler C. E., Summers J. Cloning and structural analysis of integrated woodchuck hepatitis virus sequences from a chronically infected liver. J Virol. 1984 Jun;50(3):832–837. doi: 10.1128/jvi.50.3.832-837.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Rossner M. T. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol. 1992 Feb;36(2):101–117. doi: 10.1002/jmv.1890360207. [DOI] [PubMed] [Google Scholar]
  101. Sandgren E. P., Palmiter R. D., Heckel J. L., Brinster R. L., Degen J. L. DNA rearrangement causes hepatocarcinogenesis in albumin-plasminogen activator transgenic mice. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11523–11527. doi: 10.1073/pnas.89.23.11523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Sandgren E. P., Quaife C. J., Pinkert C. A., Palmiter R. D., Brinster R. L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene. 1989 Jun;4(6):715–724. [PubMed] [Google Scholar]
  103. Schaeffer L., Roy R., Humbert S., Moncollin V., Vermeulen W., Hoeijmakers J. H., Chambon P., Egly J. M. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science. 1993 Apr 2;260(5104):58–63. doi: 10.1126/science.8465201. [DOI] [PubMed] [Google Scholar]
  104. Schek N., Bartenschlager R., Kuhn C., Schaller H. Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccinia virus. Oncogene. 1991 Oct;6(10):1735–1744. [PubMed] [Google Scholar]
  105. Schreck R., Rieber P., Baeuerle P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991 Aug;10(8):2247–2258. doi: 10.1002/j.1460-2075.1991.tb07761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Seeger C., Baldwin B., Hornbuckle W. E., Yeager A. E., Tennant B. C., Cote P., Ferrell L., Ganem D., Varmus H. E. Woodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host. J Virol. 1991 Apr;65(4):1673–1679. doi: 10.1128/jvi.65.4.1673-1679.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Seifer M., Höhne M., Schaefer S., Gerlich W. H. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J Hepatol. 1991;13 (Suppl 4):S61–S65. doi: 10.1016/0168-8278(91)90026-8. [DOI] [PubMed] [Google Scholar]
  108. Sells M. A., Zelent A. Z., Shvartsman M., Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol. 1988 Aug;62(8):2836–2844. doi: 10.1128/jvi.62.8.2836-2844.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Service R. F. Stalking the start of colon cancer. Science. 1994 Mar 18;263(5153):1559–1560. doi: 10.1126/science.8128240. [DOI] [PubMed] [Google Scholar]
  110. Service R. Slow DNA repair implicated in mutations found in tumors. Science. 1994 Mar 11;263(5152):1374–1374. doi: 10.1126/science.8128217. [DOI] [PubMed] [Google Scholar]
  111. Seto E., Mitchell P. J., Yen T. S. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature. 1990 Mar 1;344(6261):72–74. doi: 10.1038/344072a0. [DOI] [PubMed] [Google Scholar]
  112. Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12028–12032. doi: 10.1073/pnas.89.24.12028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Shirakata Y., Kawada M., Fujiki Y., Sano H., Oda M., Yaginuma K., Kobayashi M., Koike K. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res. 1989 Jul;80(7):617–621. doi: 10.1111/j.1349-7006.1989.tb01686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Simeonova P. P., Kehayov I. R., Kyurkchiev S. D. Identification of human ventricular myosin heavy chain fragments with monoclonal antibody 2F4 in human sera after myocardial necrosis. Clin Chim Acta. 1991 Sep 30;201(3):207–221. doi: 10.1016/0009-8981(91)90372-j. [DOI] [PubMed] [Google Scholar]
  115. Snyder R. L., Tyler G., Summers J. Chronic hepatitis and hepatocellular carcinoma associated with woodchuck hepatitis virus. Am J Pathol. 1982 Jun;107(3):422–425. [PMC free article] [PubMed] [Google Scholar]
  116. Soares M. B., Ishii D. N., Efstratiadis A. Developmental and tissue-specific expression of a family of transcripts related to rat insulin-like growth factor II mRNA. Nucleic Acids Res. 1985 Feb 25;13(4):1119–1134. doi: 10.1093/nar/13.4.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. St Clair W. H., St Clair D. K. Effect of the Bowman-Birk protease inhibitor on the expression of oncogenes in the irradiated rat colon. Cancer Res. 1991 Sep 1;51(17):4539–4543. [PubMed] [Google Scholar]
  118. Su Q., Liu Y. F., Zhang J. F., Zhang S. X., Li D. F., Yang J. J. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology. 1994 Oct;20(4 Pt 1):788–799. doi: 10.1002/hep.1840200404. [DOI] [PubMed] [Google Scholar]
  119. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978;24:40–69. [PubMed] [Google Scholar]
  120. Takada S., Kaneniwa N., Tsuchida N., Koike K. Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology. 1996 Feb 1;216(1):80–89. doi: 10.1006/viro.1996.0036. [DOI] [PubMed] [Google Scholar]
  121. Takada S., Kido H., Fukutomi A., Mori T., Koike K. Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor. Oncogene. 1994 Feb;9(2):341–348. [PubMed] [Google Scholar]
  122. Takada S., Koike K. X protein of hepatitis B virus resembles a serine protease inhibitor. Jpn J Cancer Res. 1990 Dec;81(12):1191–1194. doi: 10.1111/j.1349-7006.1990.tb02675.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Takada S., Tsuchida N., Kobayashi M., Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J Cancer Res Clin Oncol. 1995;121(9-10):593–601. doi: 10.1007/BF01197776. [DOI] [PubMed] [Google Scholar]
  124. Tiollais P., Pourcel C., Dejean A. The hepatitis B virus. Nature. 1985 Oct 10;317(6037):489–495. doi: 10.1038/317489a0. [DOI] [PubMed] [Google Scholar]
  125. Transy C., Fourel G., Robinson W. S., Tiollais P., Marion P. L., Buendia M. A. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3874–3878. doi: 10.1073/pnas.89.9.3874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Truant R., Antunovic J., Greenblatt J., Prives C., Cromlish J. A. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol. 1995 Mar;69(3):1851–1859. doi: 10.1128/jvi.69.3.1851-1859.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Twu J. S., Robinson W. S. Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc Natl Acad Sci U S A. 1989 Mar;86(6):2046–2050. doi: 10.1073/pnas.86.6.2046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Ueda H., Ullrich S. J., Gangemi J. D., Kappel C. A., Ngo L., Feitelson M. A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995 Jan;9(1):41–47. doi: 10.1038/ng0195-41. [DOI] [PubMed] [Google Scholar]
  129. Ueda K., Ganem D. Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. J Virol. 1996 Mar;70(3):1375–1383. doi: 10.1128/jvi.70.3.1375-1383.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Ullrich S. J., Anderson C. W., Mercer W. E., Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem. 1992 Aug 5;267(22):15259–15262. [PubMed] [Google Scholar]
  131. Van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996 Nov 1;274(5288):787–789. doi: 10.1126/science.274.5288.787. [DOI] [PubMed] [Google Scholar]
  132. Van Rensburg S. J., Cook-Mozaffari P., Van Schalkwyk D. J., Van der Watt J. J., Vincent T. J., Purchase I. F. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer. 1985 May;51(5):713–726. doi: 10.1038/bjc.1985.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Wang E. H., Friedman P. N., Prives C. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell. 1989 May 5;57(3):379–392. doi: 10.1016/0092-8674(89)90913-6. [DOI] [PubMed] [Google Scholar]
  134. Wang W. L., London W. T., Lega L., Feitelson M. A. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology. 1991 Jul;14(1):29–37. doi: 10.1002/hep.1840140106. [DOI] [PubMed] [Google Scholar]
  135. Wang W., Carey M., Gralla J. D. Polymerase II promoter activation: closed complex formation and ATP-driven start site opening. Science. 1992 Jan 24;255(5043):450–453. doi: 10.1126/science.1310361. [DOI] [PubMed] [Google Scholar]
  136. Wang X. W., Forrester K., Yeh H., Feitelson M. A., Gu J. R., Harris C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2230–2234. doi: 10.1073/pnas.91.6.2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Wang X. W., Gibson M. K., Vermeulen W., Yeh H., Forrester K., Stürzbecher H. W., Hoeijmakers J. H., Harris C. C. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995 Dec 15;55(24):6012–6016. [PubMed] [Google Scholar]
  138. Wollersheim M., Debelka U., Hofschneider P. H. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene. 1988 Nov;3(5):545–552. [PubMed] [Google Scholar]
  139. Wu J. Y., Zhou Z. Y., Judd A., Cartwright C. A., Robinson W. S. The hepatitis B virus-encoded transcriptional trans-activator hbx appears to be a novel protein serine/threonine kinase. Cell. 1990 Nov 16;63(4):687–695. doi: 10.1016/0092-8674(90)90135-2. [DOI] [PubMed] [Google Scholar]
  140. Yang D. Y., Rogler C. E. Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis. 1991 Oct;12(10):1893–1901. doi: 10.1093/carcin/12.10.1893. [DOI] [PubMed] [Google Scholar]
  141. Yang D., Faris R., Hixson D., Affigne S., Rogler C. E. Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. J Virol. 1996 Sep;70(9):6260–6268. doi: 10.1128/jvi.70.9.6260-6268.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Yeh F. S., Yu M. C., Mo C. C., Luo S., Tong M. J., Henderson B. E. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 1989 May 1;49(9):2506–2509. [PubMed] [Google Scholar]
  143. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence J. J., May P., Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol. 1993 Mar;13(3):1415–1423. doi: 10.1128/mcb.13.3.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Zahm P., Hofschneider P. H., Koshy R. The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene. 1988 Aug;3(2):169–177. [PubMed] [Google Scholar]
  145. Zambetti G. P., Levine A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993 Jul;7(10):855–865. doi: 10.1096/fasebj.7.10.8344485. [DOI] [PubMed] [Google Scholar]
  146. Zhu M., London W. T., Duan L. X., Feitelson M. A. The value of hepatitis B x antigen as a prognostic marker in the development of hepatocellular carcinoma. Int J Cancer. 1993 Oct 21;55(4):571–576. doi: 10.1002/ijc.2910550409. [DOI] [PubMed] [Google Scholar]
  147. Zoulim F., Saputelli J., Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol. 1994 Mar;68(3):2026–2030. doi: 10.1128/jvi.68.3.2026-2030.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. d'Arville C. N., Nouri-Aria K. T., Johnson P., Williams R. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology. 1991 Feb;13(2):310–315. [PubMed] [Google Scholar]
  149. de-Medina T., Haviv I., Noiman S., Shaul Y. The X protein of hepatitis B virus has a ribo/deoxy ATPase activity. Virology. 1994 Jul;202(1):401–407. doi: 10.1006/viro.1994.1356. [DOI] [PubMed] [Google Scholar]